Humanising the Digital Workforce: Navigating AI and Talent Challenges in CDMO & CRO Pharma Services

The pharmaceutical services sector is facing a pivotal moment as 2026 begins. After two years of volatility marked by funding constraints, geopolitical pressure and rapid technological change, CDMOs and CROs are coming out leaner, more digital and more strategic. Amid this transformation, people rather than infrastructure are emerging as the real constraint and differentiator in the industry’s next phase of growth. The 2026 Pharma Trends Outlook by CPHI highlights how advanced therapeutics, innovative manufacturing technologies and the adoption of artificial intelligence (AI) are reshaping the market. Yet the report also stresses that the human factor remains indispensable and that building and retaining talent will determine whether companies thrive or stall.

Talent scarcity and the need for awareness in the pharmaceutical industry

Jack Shute, Managing Director of Vector Talent, underscores a key challenge raised in the CPHI report: awareness and engagement. “There is certainly a way to evaluate an individual’s strengths, but it’s also about the individual choosing pharma as an industry to develop their career”. Many graduates look to technology, law or other sectors; the CDMO and pharma services industry simply does not appear on their radar. Shute warns that candidates often lack awareness of contract development and manufacturing organisations (CDMOs) and the broader services sector, and the same is true for the rapidly growing opportunities in data and AI. Building a talent pipeline therefore requires proactive education about the breadth of roles available and the vital role of CDMOs in bringing therapies to market.

The talent gap is widening. A 2023 Deloitte survey of 105 biopharma supply chain leaders found that while companies recognise the need to digitise, 66 % of respondents still lack clarity on how roles and skills must evolve and instead adopt reactive, short-term hiring approaches. Actalent’s 2026 workforce analysis notes that after years of stagnation, hiring is picking up, but the talent pipeline of new graduates is thinning and tech fluency remains low. This shortage is particularly acute in CDMOs, where the move toward advanced biologics, antibody‑drug conjugates (ADCs), cell and gene therapies and highly automated manufacturing demands process scientists, microbiologists and digital manufacturing specialists who simply aren’t available in sufficient numbers. Vector’s own analysis confirms that as CDMOs scale advanced manufacturing, talent availability is the primary limiting factor, with facilities often ready to operate but constrained by hiring timelines and workforce burnout.

AI adoption raises new skills expectations in pharma services

The CPHI report emphasises that AI is integrated across the pharmaceutical value chain – from drug discovery and clinical trial design to manufacturing processes and post‑market surveillance. At the same time, it warns that regulatory frameworks and corporate policies are struggling to keep pace with the technology. The market’s focus on AI is mirrored in industry surveys: according to a 2026 outlook by ZS Associates, digital infrastructure, AI‑enabled clinical tools and connected care models are moving from hype to practical implementation, and companies are doubling down on AI investment in R&D. This acceleration means that employers need scientists and engineers who are comfortable working alongside AI tools, using predictive modelling, digital twins and generative platforms to speed up research and development. In practice, however, only 22 % of life-science leaders have been able to scale AI successfully, and only 9 % report significant return on investment.

Shute points out that domain knowledge remains essential. Hiring candidates with expertise in machine-learning algorithms alone is not enough. AI engineers must understand protein structures, biology and regulatory constraints. As he notes, “It’s crucial to build a talent pipeline to attract and develop the right expertise in these fields”. The CPHI report echoes this sentiment, noting that while AI can generate dossiers and support regulatory submissions, there is a risk of fabricated or overly elaborate content and regulators must be able to distinguish genuine work from AI-generated output.

Industry guidance suggests three practical responses:

1. Hire for AI fluency and scientific literacy. Workforce analyses recommend seeking scientists who not only understand AI tools but can strategically deploy them in R&D and manufacturing. Cross‑functional talent that bridges science, operations, technology and regulation will be in highest demand.
2. Invest in reskilling and upskilling. With AI taking over repetitive tasks, professionals must pivot toward higher‑value analytical roles. Many companies now prioritise internal training to build digital literacy rather than relying solely on external hires; this strategy fills AI skills gaps and improves retention.
3. Maintain the human element. Despite automation, the human factor remains indispensable. The CPHI report highlights concerns that AI‑generated regulatory dossiers could overwhelm authorities and that high‑quality datasets and scientific oversight are necessary for trustworthy models. Firms must therefore preserve rigorous scientific and ethical standards while leveraging AI.

Competing for cross‑industry talent: CDMO and CRO recruiting strategies

Life sciences is not the only sector hunting for digital skills. Shute observes that graduates can go into tech, law or a host of other fields, and CDMOs must compete with big tech and other industries for data scientists, software engineers and automation specialists. Reshoring initiatives further intensify the competition: as manufacturing returns to Europe and North America, CDMOs find themselves competing with pharma, biotech and adjacent industries for the same scarce expertise. Hiring delays, skills gaps and workforce burnout can render new facilities idle.

Other sectors also highlight the pressure. Contract Pharma’s 2026 trend outlook notes that companies across biopharma are struggling to maintain fully staffed workforces due to ongoing talent shortages and that investments in training and cross-functional expertise will grow in 2026 to meet operational demands. Organizations that create dynamic work environments, support physical and mental health and implement automation and digitalization tools for onboarding will be more competitive in attracting top-tier talent.

Building a future‑ready workforce for CDMOs and CROs

To close the talent gap, organisations must treat workforce planning as a strategic exercise. According to Vector Talent’s analysis, digital fluency is non‑negotiable in 2026; professionals who can work confidently with automation systems, data platforms and AI‑enabled tools are in highest demand, and employers are prioritising cross-functional talent that can bridge science, operations, technology and regulation. Regulatory, quality and ESG expertise are also rising in importance as global compliance expectations tighten and sustainability becomes embedded in business strategy.

Moreover, workforce scarcity is reshaping corporate strategy. Unemployment across life sciences remains low while vacancy rates are high; many organizations operate below capacity due to staffing constraints even as they invest heavily in infrastructure and technology. This reality is driving a shift toward data-driven workforce planning, predictive skills mapping and internal mobility initiatives. Companies that align their talent strategies with employee expectations—including remote and hybrid work, meaningful career development and purpose-led cultures—will lower attrition and unlock stronger operational performance.

Why 2026 is a moment for optimism

Despite the challenges, the outlook for 2026 is fundamentally positive. Investment in CDMO capacity remains strong; CRO market growth continues apace; and innovation across modalities, digital platforms and trial design is accelerating. Recognising that talent strategy is business strategy, industry leaders have the opportunity to build resilient, future-ready teams that fully leverage technological advancements. Professionals who combine scientific expertise with digital skills, adaptability and a global mindset will thrive in this environment.

Shute’s comments in the CPHI report encapsulate the imperative facing the pharma services sector: educate potential talent about the opportunities in CDMOs, invest in skills development, and integrate human expertise with AI capabilities. By humanising the digital workforce and treating talent as the core infrastructure of the organisation, CDMOs and CROs can navigate the AI-driven future and deliver breakthrough therapies more effectively. The companies that succeed will be those that see beyond infrastructure to the people powering innovation – ensuring that the next generation chooses pharma not by accident, but by design.

‍